Log in or Sign up for Free to view tailored content for your specialty!
Esophagus News
Takeda’s Eohilia rebounds to win FDA approval as ‘first and only’ oral therapy for EoE
The FDA has approved Takeda Pharmaceuticals’ Eohilia as the “first and only oral therapy” for treatment of eosinophilic esophagitis in patients aged 11 years or older, according to a press release.
Cyted snags FDA 510(k) clearance for non-endoscopic esophageal precancer test
The FDA granted 510(k) clearance to Cyted’s EndoSign, a non-endoscopic capsule sponge device intended to gather pan-esophageal samples for early detection of esophageal cancer as well as other conditions, according to a company release.
Log in or Sign up for Free to view tailored content for your specialty!
Immune-resetting peptide gets orphan drug designation for eosinophilic esophagitis
The FDA has granted an orphan drug designation to ’1104 from Revolo Biotherapeutics, a first-in-class immune-resetting peptide designed to treat eosinophilic esophagitis, according to a press release.
Q&A: Improved outcomes anticipated with dupilumab for children with EoE
Treatment options for children with eosinophilic esophagitis have expanded with the FDA’s approval of dupilumab for those aged 1 to 11 years who weigh at least 15 kg, according to a press release.
FDA approves dupilumab for children with eosinophilic esophagitis
The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in children aged 1 to 11 years who weigh at least 15 kg, according to a press release.
On-demand vonoprazan may replace daily therapy for nonerosive reflux disease
Researchers reported that on-demand vonoprazan may be a “reasonable alternative” to daily therapy for heartburn, after demonstrating complete and sustained relief of more heartburn episodes than placebo.
Etrasimod 2 mg reduces peak eosinophil count at week 16, improves symptom severity
VANCOUVER, British Columbia — Once-daily etrasimod 2 mg was well-tolerated and reduced peak eosinophil count at week 16 in patients with eosinophilic esophagitis, according to data presented at the ACG Annual Scientific Meeting.
Dupilumab sustains histologic, endoscopic improvement up to 1 year in children with EoE
VANCOUVER, British Columbia — High-dose dupilumab achieved significant improvements in histologic and endoscopic measures through 52 weeks in children aged 1 to 11 years with eosinophilic esophagitis, according to late-breaking data.
Voquezna back on track with FDA approval for erosive esophagitis, heartburn relief
The FDA has approved Phathom Pharmaceuticals’ Voquezna tablets 10 mg and 20 mg to treat erosive esophagitis, or erosive gastroesophageal reflux disease, and alleviate heartburn associated with the disease, noted a company release.
World Trade Center firefighters using inhaled medication, steroids at risk for GERD
HONOLULU — Use of short-acting beta agonists and steroids each raised the likelihood for gastroesophageal reflux disease among firefighters exposed to 9/11 particulate matter, according to a presentation at the CHEST Annual Meeting.
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read